(MENAFN- Swissinfo)
Basel researchers successfully tested the vaccine on hamsters using nasal drops. The vaccine effectively protected them against the disease and prevented virus transmission. University of Basel, Catherine Weyer
Researchers at the University of Basel have successfully tested a new Covid vaccine in animal studies. Based on modified coronaviruses, the vaccine would be administered orally or nasally. Clinical trials in humans are due to follow.
This content was published on May 23, 2023 May 23, 2023 Keystone-SDA/sb Português
(pt)
nova vacina contra a covid-19 é testada com sucesso na suíça
The vaccine is based on a“modified coronavirus that can enter body cells and trigger an effective immune response but cannot multiply in the body”, the university said in a statementexternal link on Monday.
The new“single-cycle” vaccine is based on a specially adapted version of the virus that can be produced in a laboratory. In cells of the vaccinated person, however, the single-cycle virus cannot replicate further after the initial entry.
+ swiss claim covid vaccine success despite side-effects
“Among other things, we remove a specific gene from the blueprint for the viral envelope,” explained Thomas Klimkait of the Department of Biomedicine at the University of Basel. If this envelope component is missing, no new virus particles can be formed. Yet, the body cells still produce the remaining components of the virus and present them on their surface to the immune system, which recognises the viral components and builds up effective immune protection.
Basel researchers successfully tested the vaccine on hamsters using nasal drops. The vaccine effectively protected them against the disease and prevented virus transmission.
+ coronavirus: the situation in switzerland
The new vaccine concept, developed in collaboration with the company RocketVax, can also be rapidly adapted to new variants and even to other viruses, the researchers claim.
“Although safe and effective COVID-19 vaccines have been available since early 2021, SARS-CoV-2 continues to spread, with new variants continuously emerging. In some regions, the population lacks access to vaccines; in others, there is a lack of confidence in the novel mRNA vaccines. New vaccines that are easy to store and administer and that build up effective immune protection would be an important step toward keeping the SARS-CoV-2 coronavirus at bay in the long term,” the university said in its statement.
MENAFN23052023000210011054ID1106299881
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.